- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00341055
A Study to Evaluate the Hematologic Response Rate (the Rate at Which the Hemoglobin Level Rises) of PROCRIT (Epoetin Alfa) Given at a Dose of 80,000 Units Once Weekly to Cancer Patients With Anemia Who Are Receiving Chemotherapy.
A Pilot Study to Evaluate the Hematologic Response Rate of PROCRIT� (Epoetin Alfa) at 80,000 Units Once Weekly in Anemic Cancer Patients Receiving Chemotherapy
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
When comparing the proposed study dose to current literature, the initial study dose of 80,000 Units administered once per week is equivalent to an individual dose of 1142 Units/kg body weight for a 70 kg patient. It is also common in clinical practice for anemic cancer patients to be treated with a dose of PROCRIT (Epoetin alfa) of 40,000 Units weekly. This study was an open-label, non-randomized pilot study of cancer patients with non-myeloid malignancies with a hemoglobin < = 11 g/dL planned to receive at least 12 weeks of chemotherapy. The objective of the study was to evaluate the hematologic response, safety, and clinical outcomes of PROCRIT (Epoetin alfa) at 80,000 Units given subcutaneously (under the skin) once weekly in anemic cancer patients receiving chemotherapy. If, at any time the hemoglobin was > 13 g/dL, PROCRIT (Epoetin alfa) therapy was held until the hemoglobin was <= 12 g/dL, then resumed at 60,000 Units once weekly. The dose was also reduced if the hemoglobin rose by > 1.3 g/dL in a 2 week period.
Additionally, the incidence of anti-erythropoietin antibodies at baseline and at end of study/early withdrawal in study patients who have received a minimum of two or more doses of PROCRIT (Epoetin alfa) over at least a one-month period was evaluated. Rarely, antibodies to erythropoietin may form in patients who have some types of diseases (e.g., autoimmune diseases, rheumatoid arthritis, anemia of chronic disease) or in response to exposure to erythropoietin products such as Epoetin alfa necessitating discontinuation of the erythropoietin agent and medical treatment that may include blood transfusions. Hemoglobin level, vital signs (blood pressure) and occurrence and severity of adverse events was assessed throughout the study. PROCRIT (Epoetin alfa) was given at a dose of 80,000 Units subcutaneously (under the skin) for 12 weeks. The PROCRIT (Epoetin alfa) dose was monitored throughout the study and the dose was withheld or reduced as necessary to maintain hemoglobin level and rate of hemoglobin rise.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 3
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Patients with a confirmed diagnosis of any non-myeloid malignancy planned to have received at least 12 weeks of chemotherapy with hemoglobin <= 11 g/dL
- Life expectancy > 6 months with Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
- Both male and female patients with reproductive potential must have used an adequate contraceptive method (e.g., abstinence, intrauterine device, oral contraceptives, barrier device with spermicide or surgical sterilization) during treatment and for three months after completing treatment. Female patients with reproductive potential had a negative serum pregnancy test within 7 days of the first dose of study drug.
Exclusion Criteria:
- Previous radiation therapy to > 25% bone marrow reserve or planned radiation during study duration
- Packed red blood cells (PRBC) transfusion within 28 days of study entry
- Anemia due to factors other than cancer/chemotherapy, i.e., iron, folate, Vitamin B12 deficiency, hemolysis or GI bleeding
- Previous treatment with Epoetin alfa or any investigational forms of erythropoietin (e.g., gene-activated erythropoietin, novel erythropoiesis stimulating protein) within the previous 3 months
- uncontrolled hypertension or history of thrombotic vascular events
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
---|
The primary efficacy endpoint was major response defined as the proportion of patients with >= 2 g/dL hemoglobin (Hb) increase from baseline or Hb >= 12 g/dL and independent of transfusion within 28 days.
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
---|
The secondary efficacy endpoint was minor response defined as the proportion of patients with >= 1 g/dL hemoglobin (Hb) increase from baseline (up to 1.9 g/dL increase) and incidence of transfusion and independent of transfusion within 28 days.
|
Mitarbeiter und Ermittler
Publikationen und hilfreiche Links
Nützliche Links
- A Pilot Study to Evaluate the Hematologic Response Rate of PROCRIT (Epoetin alfa) at 80,000 Units Once Weekly in Anemic Cancer Patients Receiving Chemotherapy
- |Waltzman RJ, Williams D, Braly P. A Pilot Study to Evaluate the Safety and Clinical Outcomes of Once-Weekly Epoetin Alfa 80,000 U in Anemic Patients With Cancer Receiving Chemotherapy. Supportive Cancer Therapy. 2005;3(1):47-53
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- CR005110
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Epoetin alfa
-
University of WashingtonNational Institute of Neurological Disorders and Stroke (NINDS)AbgeschlossenExtreme FrühgeburtlichkeitVereinigte Staaten
-
ShireAbgeschlossenMorbus FabryVereinigte Staaten
-
Johnson & Johnson Pharmaceutical Research & Development...Ortho Biotech Clinical Affairs, L.L.C.BeendetNeubildungen | Krebs | AnämieVereinigte Staaten
-
Jonsson Comprehensive Cancer CenterAmgenAbgeschlossenLymphom | Leukämie | Anämie | Nicht näher bezeichneter erwachsener solider Tumor, protokollspezifisch | Multiples Myelom und Plasmazell-Neoplasma | Lymphoproliferative Störung | Präkanzeröser/nicht bösartiger ZustandVereinigte Staaten
-
Philogen S.p.A.RekrutierungKarzinom, Basalzelle | Karzinom, kutane PlattenepithelzellenDeutschland, Polen, Schweiz
-
Novo Nordisk A/SAbgeschlossenAngeborene Blutungsstörung | Hämophilie A mit Inhibitoren | Hämophilie B mit InhibitorenTaiwan, Vereinigtes Königreich, Thailand, Serbien, Kroatien, Italien, Polen, Rumänien, Ungarn, Malaysia, Vereinigte Staaten, Österreich, Brasilien, Griechenland, Japan, Puerto Rico, Russische Föderation, Südafrika, Truthahn
-
University of California, San FranciscoDuke UniversityRekrutierungWolman-Krankheit | MPS IVA | Morbus Pompe Infantiler Beginn | Gaucher-Krankheit, Typ 2 | MPS VI | MPS I | Gaucher-Krankheit, Typ 3 | MPS II | Mps VIIVereinigte Staaten
-
Philogen S.p.A.RekrutierungKaposi-Sarkom | Merkelzellkarzinom | BCC - Basalzellkarzinom | SCC – Plattenepithelkarzinom | Keratoakanthom der Haut | Maligne Adnextumore der Haut (MATS) | Tumore des kutanen T-Zell-Lymphoms (CTCL)Spanien, Frankreich, Italien
-
Hoffmann-La RocheBeendetIdiopathische LungenfibroseKorea, Republik von, Vereinigte Staaten, Frankreich, Israel, Spanien, Belgien, Australien, Tschechien, Dänemark, Taiwan, Italien, Japan, Singapur, Truthahn, Deutschland, China, Neuseeland, Argentinien, Portugal, Südafrika, Ungarn, Kanad... und mehr